5 May 2017

Holding(s) in Company



Read more

5 May 2017

Holding(s) in Company

Read more

5 May 2017

Holding(s) in Company

 

Read more

3 May 2017

Holding(s) in Company

 

Read more

3 May 2017

Block Listing Application and Review

Verona Pharma plc

Read more

3 May 2017

Grant of Options and RSUs and PDMR Dealings

Grant of Options and RSUs and PDMR Dealings

Read more

2 May 2017

Verona Pharma Announces Closing of Global Offering

LONDON, May 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signific…

Read more

2 May 2017

Closing of Global Offering and Total Voting Rights

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

Read more

2 May 2017

Director/PDMR Shareholding

This is a re-release of the Verona Pharma plc announcement released on 28 April 2017 at 17.40 under RNS No 7827D.

Read more

28 April 2017

Director/PDMR Shareholding

 

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us